Atea’s antiviral treatment combo works for 98% of HCV patients
Note: This story was updated Aug. 22, 2024, to clarify the timeline detailing the results of treatment. Atea Pharmaceuticals’ once-daily oral antiviral treatment for…
Hepatitis
Many viruses behind 2022 outbreak of hepatitis in children: Study
A global outbreak of severe hepatitis in children just after COVID-19 restrictions were lifted could have been caused by infections with multiple viruses at…
Many patients face barriers in accessing treatments for hepatitis C
While highly effective treatments for hepatitis C are available worldwide, many people — especially those living in poorer countries — are not able to access…
GSK’s hepatitis B candidate bepirovirsen wins fast track status
The U.S. Food and Drug Administration (FDA) has granted fast track status to bepirovirsen, GlaxoSmithKline (GSK)’s candidate treatment for chronic hepatitis B (CHB),…
Canada funds projects to curb hepatitis C, blood-borne infections
Community-based organizations in Canada addressing hepatitis C, the human immunodeficiency virus (HIV), and other sexually transmitted and blood-borne infections (STBBIs) will receive more than…
Antiviral duo found effective for hepatitis E despite virus mutations
A combination of the antiviral medications ribavirin and sofosbuvir efficiently cleared the hepatitis E virus (HEV) from two chronically infected patients despite the emergence of…
Australian Researchers Investigate Zinc as Potential Ally Against Liver Disease
A study by Australia’s Westmead Institute has revealed an unexpected role for zinc in liver disease. Researchers at the institute’s Storr Liver Center showed that…
New ‘Liver Line’ Online Community to Share Updates on Health, Research, Treatments
A new online community, called Liver Line and sponsored by Galectin Therapeutics, offers the latest information on liver health and research into liver diseases. On Liver…
Coffee Intake May Reduce Risk of Chronic Liver Disease, Study Says
Drinking coffee may reduce the risk of chronic liver disease, especially in patients with other conditions affecting the liver, including non-alcoholic fatty liver disease, according…
Recent Posts
- How I’m learning to cope with challenges as a rare disease parent
- IBAT inhibitors have potential to boost life quality for patients
- Trial of HBV treatment candidate now enrolling final patient group
- Cour’s CNP-104 granted FDA orphan drug status for treating PBC
- Maralixibat Phase 3 trial for cholestasis-related itch is enrolling